|
Patient characteristics
|
Number (n=143)
|
|---|
|
Median age (range)
|
54 (30–81)
|
|
FIGO stage
|
|
I
|
82 (57%)
|
|
II
|
20 (14%)
|
|
III
|
28 (20%)
|
|
IV
|
13 (9%)
|
|
Histology
|
|
Pure type
|
134 (94%)
|
|
Mixed type
|
9 (6%)
|
|
Serous
|
4 (3%)
|
|
Mucinous
|
2 (1%)
|
|
Endometrioid
|
2 (1%)
|
|
Cystadenocarcinofibroma
|
1 (1%)
|
|
Positive peritoneal cytology
|
66 (46%)
|
|
Endometriosis
|
|
Present
|
74 (52%)
|
|
Absent
|
69 (48%)
|
|
Treatment
|
|
Surgery
|
143 (100%)
|
|
Lymph node adenectomy
|
112 (78%)
|
|
Lymph node sampling
|
5 (3%)
|
|
Chemotherapy
|
136 (95%)
|
|
Platinum
|
135 (94%)
|
|
Taxane
|
122 (85%)
|
|
CPT-11
|
19 (13%)
|
|
Residual tumor present
|
20 (14%)
|
- FIGO International Federation of Gynecology and Obstetrics, CPT-11 camptothecin-11
